Cargando…

Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro

Since the end of 2019, the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic. There is an urgent need for effective and low-toxic antiviral drugs to remedy Remdesivir’s limitation. Hydroxychloroquine, a broad spectrum anti-viral drug, showed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Yong, Liao, Jinbiao, Qian, Zhenlong, Wu, Chunxiu, Zhang, Xiangyu, Zhang, Ji, Xie, Youhua, Jiang, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606320/
https://www.ncbi.nlm.nih.gov/pubmed/34875467
http://dx.doi.org/10.1016/j.bmc.2021.116523
_version_ 1784602320238018560
author Ni, Yong
Liao, Jinbiao
Qian, Zhenlong
Wu, Chunxiu
Zhang, Xiangyu
Zhang, Ji
Xie, Youhua
Jiang, Sheng
author_facet Ni, Yong
Liao, Jinbiao
Qian, Zhenlong
Wu, Chunxiu
Zhang, Xiangyu
Zhang, Ji
Xie, Youhua
Jiang, Sheng
author_sort Ni, Yong
collection PubMed
description Since the end of 2019, the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic. There is an urgent need for effective and low-toxic antiviral drugs to remedy Remdesivir’s limitation. Hydroxychloroquine, a broad spectrum anti-viral drug, showed inhibitory activity against SARS-CoV-2 in some studies. Thus, we adopted a drug repurposing strategy, and further investigated hydroxychloroquine. We obtained different configurations of hydroxychloroquine side chains by using chiral resolution technique, and successfully furnished R-/S-hydroxychloroquine sulfate through chemical synthesis. The R configuration of hydroxychloroquine was found to exhibit higher antiviral activity (EC50 = 3.05 μM) and lower toxicity in vivo. Therefore, R-HCQ is a promising lead compound against SARS-CoV-2. Our research provides new strategy for the subsequent research on small molecule inhibitors against SARS-CoV-2.
format Online
Article
Text
id pubmed-8606320
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-86063202021-11-22 Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro Ni, Yong Liao, Jinbiao Qian, Zhenlong Wu, Chunxiu Zhang, Xiangyu Zhang, Ji Xie, Youhua Jiang, Sheng Bioorg Med Chem Article Since the end of 2019, the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic. There is an urgent need for effective and low-toxic antiviral drugs to remedy Remdesivir’s limitation. Hydroxychloroquine, a broad spectrum anti-viral drug, showed inhibitory activity against SARS-CoV-2 in some studies. Thus, we adopted a drug repurposing strategy, and further investigated hydroxychloroquine. We obtained different configurations of hydroxychloroquine side chains by using chiral resolution technique, and successfully furnished R-/S-hydroxychloroquine sulfate through chemical synthesis. The R configuration of hydroxychloroquine was found to exhibit higher antiviral activity (EC50 = 3.05 μM) and lower toxicity in vivo. Therefore, R-HCQ is a promising lead compound against SARS-CoV-2. Our research provides new strategy for the subsequent research on small molecule inhibitors against SARS-CoV-2. Elsevier Ltd. 2022-01-01 2021-11-22 /pmc/articles/PMC8606320/ /pubmed/34875467 http://dx.doi.org/10.1016/j.bmc.2021.116523 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ni, Yong
Liao, Jinbiao
Qian, Zhenlong
Wu, Chunxiu
Zhang, Xiangyu
Zhang, Ji
Xie, Youhua
Jiang, Sheng
Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
title Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
title_full Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
title_fullStr Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
title_full_unstemmed Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
title_short Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro
title_sort synthesis and evaluation of enantiomers of hydroxychloroquine against sars-cov-2 in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606320/
https://www.ncbi.nlm.nih.gov/pubmed/34875467
http://dx.doi.org/10.1016/j.bmc.2021.116523
work_keys_str_mv AT niyong synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro
AT liaojinbiao synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro
AT qianzhenlong synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro
AT wuchunxiu synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro
AT zhangxiangyu synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro
AT zhangji synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro
AT xieyouhua synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro
AT jiangsheng synthesisandevaluationofenantiomersofhydroxychloroquineagainstsarscov2invitro